GlassScriptPhysician profile
Beth Ann Zavell
NPI 1225031933
$6,005.46
in general payments reported to CMS, 2019-2025
29 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $234 · 2021: $664 · 2022: $1,092 · 2023: $880 · 2024: $1,156 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,087 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,086.95 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,356.76 | 2019-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $766.37 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $598.64 | 2019-2025 | |
| Lilly USA, LLC | $407.65 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $370.86 | 2019-2025 | |
| Janssen Biotech, INC. | $363.48 | 2020-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $253.05 | 2019-2025 | Dupixent |
| Allergan, INC. | $249.00 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $219.59 | 2019-2025 | Ilumya |
| Leo Pharma INC. | $212.18 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $209.10 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $133.20 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $123.70 | 2021-2025 | Nemluvio, Aklief |
| Pfizer INC. | $98.05 | 2019-2025 | |
| Amgen INC. | $85.08 | 2020-2024 | Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $71.42 | 2022-2025 | Klisyri, Seysara |
| Verrica Pharmaceuticals INC. | $68.10 | 2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $66.46 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $65.76 | 2024 | Zoryve |
| Genentech USA, INC. | $56.23 | 2019 | |
| Dusa Pharmaceuticals, INC. | $34.51 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.09 | 2022-2024 | Siliq |
| Epi Health, LLC | $30.48 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.48 | 2023-2024 | Cyltezo, Spevigo |
| Journey Medical Corporation | $27.48 | 2023 | |
| Celgene Corporation | $23.38 | 2019 | |
| Dermira, INC. | $18.54 | 2021 | |
| Prugen, INC. Pharmaceuticals | $17.30 | 2019 | |
| Sandoz INC. | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Zavell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.